Craig-Hallum analyst Bill Bonello recommends buying shares of GeneDx (WGS), even after the 19% jump on the American Academy of Pediatrics news on Monday afternoon, the analyst tells investors in a research note. The firm, which has a Buy rating and $114 price target on the shares, expects exome and genome testing to become the standard of care for pediatric rare diseases over time, and says the AAP guidance is another reason to believe.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx Holdings: Navigating Market Opportunities and Delayed Financial Impact Amid AAP Testing Guidelines Update
- Galatea Bio, Fabric Genomics partner on genetic testing for common diseases
- GeneDx Holdings Approves Key Proposals at Annual Meeting
- Insiders Pour Millions into These 3 Stocks — Here’s Why They Draw Plaudits Across the Board
- GeneDx Holdings: Strategic Initiatives and Market Positioning Signal Strong Growth Potential